Phase II Study of Ibritumomab Tiuxetan (Zevalin) in Patients With Previously Untreated Marginal Zone Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Marginal-zone-B-cell-lymphoma
- Focus Therapeutic Use
- 31 Dec 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 18 Apr 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 04 Aug 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.